LogicBio Therapeutics Inc (NASDAQ:LOGC) reached a new 52-week high during trading on Wednesday . The stock traded as high as $12.92 and last traded at $12.60, with a volume of 606 shares. The stock had previously closed at $11.50.
In related news, Director Daniel P. O’connell purchased 700,000 shares of the business’s stock in a transaction dated Tuesday, October 23rd. The stock was acquired at an average price of $10.00 per share, for a total transaction of $7,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
WARNING: “LogicBio Therapeutics (LOGC) Reaches New 52-Week High at $12.92” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/logicbio-therapeutics-logc-reaches-new-52-week-high-at-12-92.html.
LogicBio Therapeutics Company Profile (NASDAQ:LOGC)
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.